Valvular heart diseaseDesign and Baseline Characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study
Section snippets
Study aim
The primary objective of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study is to investigate whether intensive lipid lowering with E/S combination therapy will reduce the need for aortic valve replacement and the risk of cardiovascular morbidity and mortality.
Patient population and study design
The SEAS Study is a multicenter, double-blind, randomized, placebo-controlled study. Eligible patients had asymptomatic AS defined as aortic valve thickening using echocardiographic evaluation accompanied by a Doppler-measured
Discussion
Baseline characteristics of the SEAS Study population show that most traditional risk factors for cardiovascular disease are increased, as seen in other large population studies of AS.1, 3 Because of important exclusion criteria being necessary for ethical reasons, the study population may appear as a selected one. Few patients have signs of metabolic syndrome (probably because of exclusion of patients with diabetes), high-density lipoprotein cholesterol level is relatively high, and the
Acknowledgement
We acknowledge the work done by all Merck clinical research staff in facilitating the study and the clinical investigators and study site staff.
References (11)
- et al.
Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample
J Am Coll Cardiol
(1993) - et al.
Clinical factors associated with calcific aortic valve disease
J Am Coll Cardiol
(1997) - et al.
Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in the elderly patients
Am J Cardiol
(1987) - et al.
Diabetes and hypercholesterolemia among patients with calcific aortic stenosis
J Chronic Dis
(1984) - et al.
Case-control analysis of risk factors for presence of aortic stenosis in adults (age 50 years or older)
Am J Cardiol
(1985)
Cited by (145)
Impact of estimated left atrial volume on prognosis in patients with asymptomatic mild to moderate aortic valve stenosis
2019, International Journal of CardiologyRelation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis
2019, American Journal of CardiologyImpact of Obesity on Persistent Left Ventricular Hypertrophy After Aortic Valve Replacement for Aortic Stenosis
2019, American Journal of CardiologyEffect of simvastatin and ezetimibe on suPAR levels and outcomes
2018, Atherosclerosis
This work was supported by the pharmaceutical company MSP Singapore Company, LLC, Singapore, a partnership between Merck & Co., Inc., and the Schering-Plough Corporation.